Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$693.45M, compared with -$615.65M a year earlier.

Context

  • Retained earnings amounted to 579.6% of total assets at the end of Q1 FY2026, up 143.8 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -12.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$693.45M-1.5% QoQ
Last fiscal yearDec 2025
-$683.06M-17.1% YoY
Year agoMar 2025
-$615.65M-12.6% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.6%——
1 year-17.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(683.06M) USD
Year-over-year change
-17.1%

Retained Earnings vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -12.6% is the highest of 11, against a peer median of -21.7%.
  • Retained earnings amounts to 579.6% of total assets for PRLD, versus a peer median of 337.2%.
PRLD Competitors
Retained Earnings for PRLD and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
EPRXEupraxia Pharmaceuticals Inc.Mar 2026-$182.83M USD-32.7%—125.4%
IVAInventiva S.A.Dec 2025-€354.14M EUR-92.2%—142.3%
OBIOOrchestra BioMed Holdings, Inc.Mar 2026-$383.27M USD-16.6%—380.8%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026-$429.96M USD-16.8%—136.6%
PYXSPyxis Oncology, Inc.Mar 2026-$466.45M USD-21.2%—725.4%
AVTXAvalo Therapeutics, Inc.Mar 2026-$468.15M USD-22.1%—468.7%
CRBUCaribou Biosciences, Inc.Mar 2026-$621.6M USD-27.3%—417.2%
TNYATenaya Therapeutics, Inc.Mar 2026-$624.28M USD-15.3%—462.2%
FHTXFoghorn Therapeutics Inc.Mar 2026-$652.34M USD-13.1%—293.6%
PRLDPrelude Therapeutics IncorporatedMar 2026-$693.45M USD-12.6%—579.6%
IMRXImmuneering CorporationMar 2026-$293.78B USD-122645.6%—136.8%
Peer median (excluding PRLD) —-21.7%—337.2%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents31.83M30.61M25.29M12.47M35.26M
Short-term Investments259.41M171.12M207.64M121.14M67.96M
Net Receivables00000
Inventory00000
Other Current Assets02.65M2.65M2.28M2.48M
Total Current Assets295.12M204.38M235.59M135.9M105.69M
Property, Plant & Equipment (Net)5.64M6.7M37.74M35.47M32.28M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets4.35M9.42M4.34M4.15M3.35M
Total Non-current Assets9.98M16.12M42.08M39.62M35.62M
Total Assets305.1M220.5M277.67M175.52M141.32M
Account Payables7.84M6.78M4.58M7.73M3.98M
Short-term Debt00000
Tax Payables00000
Deferred Revenue000033.73M
Other Current Liabilities5.01M6.21M6.61M9.79M5.4M
Total Current Liabilities19.2M21.7M21.83M25.64M52.99M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00001.8M
Other Non-current Liabilities03.36M3.34M3.09M2.84M
Total Non-current Liabilities03.36M18.75M18.42M19.68M
Total Liabilities19.2M25.06M40.58M44.06M72.68M
Common Stock5K5K5K5K5K
Retained Earnings(219.12M)(334.56M)(456.39M)(583.56M)(683.06M)
Accumulated OCI(711K)(1.69M)223K35K8K
Other Stockholders Equity00000
Minority Interest00000
Total Equity285.9M195.44M237.09M131.46M68.64M
Total Debt1.74M1.83M16.89M18.03M17.79M
Net Debt(30.09M)(28.77M)(8.4M)5.55M(17.47M)

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.